EYE

Nova Eye MedicalASX:EYE Stock Report

Market Cap

AU$56.0m

7D

4.1%

1Y

16.7%

Updated

16 Sep, 2021

Data

Company Financials
EYE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

EYE Overview

Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services medical devices to treat eye diseases.

Nova Eye Medical Competitors

Novartis

SWX:NOVN

CHF175.0b

Alcon

SWX:ALC

CHF39.2b

Carl Zeiss Meditec

XTRA:AFX

€17.6b

Bausch Health Companies

NYSE:BHC

US$10.1b

Price History & Performance

Summary of all time highs, changes and price drops for Nova Eye Medical
Historical stock prices
Current Share PriceAU$0.39
52 Week HighAU$0.29
52 Week LowAU$0.58
Beta0.53
1 Month Change-10.47%
3 Month Change26.23%
1 Year Change16.67%
3 Year Change-53.33%
5 Year Change-65.00%
Change since IPO-35.06%

Recent News & Updates

Jan 04
Nova Eye Medical (ASX:EYE) Shares Have Generated A Total Return Of Negative 19% In The Last Three Years

Nova Eye Medical (ASX:EYE) Shares Have Generated A Total Return Of Negative 19% In The Last Three Years

Nova Eye Medical Limited ( ASX:EYE ) shareholders should be happy to see the share price up 13% in the last quarter...

Shareholder Returns

EYEAU Medical EquipmentAU Market
7D4.1%-1.0%0.9%
1Y16.7%10.5%27.3%

Return vs Industry: EYE exceeded the Australian Medical Equipment industry which returned 8.4% over the past year.

Return vs Market: EYE underperformed the Australian Market which returned 25.6% over the past year.

Price Volatility

Is EYE's price volatile compared to industry and market?
EYE volatility
EYE Beta0.53
Industry Beta0.54
Market Beta1

Stable Share Price: EYE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: EYE's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985n/an/ahttps://www.nova-eye.com

Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services medical devices to treat eye diseases. The company offers iTrack, a surgical system for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate glaucoma openangle glaucoma; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Middle East, Japan, Asia, South America, and internationally.

Nova Eye Medical Fundamentals Summary

How do Nova Eye Medical's earnings and revenue compare to its market cap?
EYE fundamental statistics
Market CapAU$56.04m
Earnings (TTM)-AU$4.36m
Revenue (TTM)AU$13.60m

4.1x

P/S Ratio

-12.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EYE income statement (TTM)
RevenueAU$13.60m
Cost of RevenueAU$2.24m
Gross ProfitAU$11.35m
ExpensesAU$15.71m
Earnings-AU$4.36m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.03
Gross Margin83.50%
Net Profit Margin-32.04%
Debt/Equity Ratio4.0%

How did EYE perform over the long term?

See historical performance and comparison

Valuation

Is Nova Eye Medical undervalued compared to its fair value and its price relative to the market?

1.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EYE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EYE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EYE is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: EYE is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EYE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EYE is good value based on its PB Ratio (1.6x) compared to the AU Medical Equipment industry average (4.9x).


Future Growth

How is Nova Eye Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nova Eye Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Nova Eye Medical performed over the past 5 years?

-41.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EYE is currently unprofitable.

Growing Profit Margin: EYE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EYE is unprofitable, and losses have increased over the past 5 years at a rate of 41.5% per year.

Accelerating Growth: Unable to compare EYE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EYE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (57.5%).


Return on Equity

High ROE: EYE has a negative Return on Equity (-12.33%), as it is currently unprofitable.


Financial Health

How is Nova Eye Medical's financial position?


Financial Position Analysis

Short Term Liabilities: EYE's short term assets (A$26.3M) exceed its short term liabilities (A$4.7M).

Long Term Liabilities: EYE's short term assets (A$26.3M) exceed its long term liabilities (A$2.0M).


Debt to Equity History and Analysis

Debt Level: EYE's debt to equity ratio (4%) is considered satisfactory.

Reducing Debt: EYE's debt to equity ratio has reduced from 16% to 4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EYE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EYE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.7% each year


Dividend

What is Nova Eye Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EYE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EYE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EYE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EYE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EYE's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Nova Eye Medical has no CEO, or we have no data on them.


Leadership Team

Experienced Management: EYE's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: EYE's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Nova Eye Medical Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Nova Eye Medical Limited
  • Ticker: EYE
  • Exchange: ASX
  • Founded: 1985
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$56.038m
  • Shares outstanding: 145.55m
  • Website: https://www.nova-eye.com

Number of Employees


Location

  • Nova Eye Medical Limited
  • 107 Rundle Street
  • Kent Town
  • South Australia
  • 5067
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 04:28
End of Day Share Price2021/09/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.